Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Topics : Blood and lymphatic diseases
  • Active substance : romiplostim
  • Active substance : eltrombopag
  • Active substance : azacitidine
  • Active substance : fer
Filter
Topic
  • Diseases and conditions (1)
  • Plus ...
    • Blood and lymphatic diseases (1)
    • Plus ...
      • Bone marrow diseases (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Chronic disease guide (1)
Date
  • Last five years (1)
Language
  • Français (1)
Active substance
  • azacitidine (1)
  • ciprofloxacine (1)
  • eltrombopag (1)
  • fer (1)
  • romiplostim (1)

Practice guidelines and other guides - 1 result

  • Bone marrow failures and other chronic cytopenias myelodysplastic syndromes

    Chronic disease guide - Posted on 20/11/2018
    Download guide
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
VGHVV8eketa2uN3d